Invasive pulmonary aspergillosis in a child with acute myeloid leukaemia: pharmacotherapy and surgical management
Journal Title: OncoReview - Year 2016, Vol 6, Issue 4
Abstract
This paper reports on diagnostic and therapeutic management of pulmonary invasive fungal disease (IFD) in a child with relapsed acute myeloid leukaemia, undergoing chemotherapy followed by hematopoietic stem cell transplantation. Surgical management with resection of the involved lung tissue was based on the location of fungal infiltrates close to large circulatory vessels. After examination of resected pulmonary tissue, a diagnosis of proven IFD was done. This case report is an example that aspergillosis is usually the cause for pulmonary IFD. Pharmacotherapy of pulmonary IFD should be based on compounds with good penetration to lung tissue: amphotericin B lipid form or voriconazole.
Authors and Affiliations
Jan Styczyński
Keywords
Related Articles
- EP ID EP186906
- DOI 10.5604/01.3001.0009.5060
- Views 202
- Downloads 0
Application of molecular markers in the diagnostics of thyroid focal lesions – current state of knowledge
Thyroid nodular disease is a common disorder and affects about 20% of adult polish population. Due to the fact that methods currently applied in routine assessment of these changes often do not provide accurate diagnosis...
Clinical usefulness of measuring the number of Circulating Tumor Cells (CTC) in breast cancer patients
Background: Monitoring the breast cancer patients after an adjuvant therapy usually involves imaging methods or biopsy. Alternatively, breast cancer markers can be determined – one of them is the number of circulating tu...
Advanced pancreatic neuroendocrine tumor patient treated with everolimus – case report
The increasing incidence of gastroenteropancreatic neuroendocrine tumors is caused not exclusively by increasing number of new cases, but also by improved diagnostics. Proper diagnosis and evaluation of tumor differentia...
Ongoing research developments in cardio-oncology
Why does reimbursement of orphan drugs require a specific approach?
The greatest problem concerning the reimbursement of orphan products is their high price. In the case of orphan drugs, reimbursement and pricing decisions are highly interrelated. In decisions concerning reimbursement of...